|Dr. Philip Frost M.D., Ph.D.||Chairman and Chief Exec. Officer||970.6k||N/A||81|
|Dr. Jane H. Hsiao Ph.D., MBA||Vice Chairman and Chief Technical Officer||970.6k||N/A||70|
|Mr. Adam E. Logal||Chief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer||610.6k||N/A||39|
|Mr. Steven D. Rubin J.D., Esq.||Exec. VP of Admin. and Director||820.6k||2.29M||55|
|Ms. Kate Inman Esq.||Deputy Gen. Counsel and Sec.||N/A||N/A||44|
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companys Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
Opko Health, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 8. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 3; Compensation: 7.